Sanome
Our long-term vision is to build a human digital twin (a virtual representation of everyone’s biology & health) that allows us to predict any changes to someone’s health before they actually occur, thus enabling true preventative healthcare.
Benedikt von Thüngen, Co-Founder & CEO
- Co-Founder & CEO
- Benedikt von Thüngen
- Co-Founder & Chief Medical Officer
- Dr. Marc van der Schee
- When we invested
- Founded
- 2021
- Partnered
- 2021
- Location
- London, Cambridge and Amsterdam
- Area
- Personalised medicine
What we do
Sanome has developed a diagnostics innovation engine that combines biomarkers to develop medical grade, at home diagnostic products (IVDs) more efficiently and effectively.
Most digital health, wearables and consumer biotech tools have limited medical use because it’s hard to validate them clinically. Sanome’s novel approach leverages these existing technologies to develop at home test that are clinically validated to improve patient outcomes and reduce healthcare costs. Ultimately, laying the foundation for the early detection and prevention of diseases of high unmet need.
Sanome is on a mission to change the paradigm of diagnostics development by developing an IVD innovation engine. We are combining different types of biomarkers to develop engaging, useful and accurate diagnostic products (IVD’s) that enable early detection and prevention of disease. This IVD innovation engine, will ultimately enable new approaches for healthcare delivery, providing access to novel at-home testing paradigms for all people.
Ultimately we want to be brining more at home tech to IVD and into consumer hands, thus monitoring health better.
- We are creating a paradigm shift in diagnostics development by making them 10x more effective, faster and impactful.
- The IVD innovation engine, will ultimately enable new approaches for healthcare delivery, providing access to novel at-home testing paradigms for all people
- The IVD innovation engine, will ultimately enable new approaches for healthcare delivery, providing access to novel at-home testing paradigms for all people
